Piotr Tomczak - Concepedia

Author

Piotr Tomczak

Poznan University of Medical Sciences ORCID

Also Known As

P Tomczak, P. Tomczak, PD Tomczak, Piotr Tomczak, Piotr Tomczak, MD, Saverio Cinieri, Tomczak, Tomczak, P., Tomczak, Piotr, Wiebren Tjalma

192

Publications

24.7K

Citations

H-Index

Concepts

All Affiliations

Poznan University of Medical Sciences Ulsan College University of Ulsan Asan Medical Center Memorial Sloan Kettering Cancer Center

About

Piotr Tomczak is an author at Poznan University of Medical Sciences specializing in cancer therapeutics, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	46	7.8K
2	Health Sciences	12	14	2K
3	Engineering	10	12	305
4	Natural Sciences	10	12	305
5	Applied Physics	8	8	192

Piotr Tomczak

Publications

24.1K

Citations

H-Index

Page 1

	Year	Citations
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, New England Journal of Medicine	2007	5.7K
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, New England Journal of Medicine	2007	3.6K
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, Journal of Clinical Oncology	2009	2.2K
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Brian I. Rini, Bernard Escudier, Piotr Tomczak, The Lancet Comparative EffectivenessUrologyOncologyAxitinib Versus SorafenibGenitourinary Cancer	2011	1.8K
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer E O’Brien, Nely Wigler, Moshe Inbar, Annals of Oncology Liposomal Doxorubicin HclMetastatic Breast CancerOncologyBreast OncologyPharmacology	2004	1.7K
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer David Miles, Arlene Chan, Luc Dirix, Journal of Clinical Oncology	2010	881
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy Alain Ravaud, Robert J. Motzer, Hardev Pandha, New England Journal of Medicine	2016	757
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Robert J. Motzer, Bernard Escudier, Piotr Tomczak, The Lancet Oncology Overall Survival AnalysisUrologyAxitinib Versus SorafenibGenitourinary CancerMedicine	2013	738
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, New England Journal of Medicine	2021	708

Page 1